Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...

Embryo-Fetal Toxicity ZIIHERA can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during p ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.67, a high estimate of $28.00, and a low estimate of $10.00. Surpassing the previous average price target ...

US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...

The U.S. Food AND Drug Administration (FDA) has granted accelerated approval of a new drug for treating bilary tract cancer ...

Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...

Zymeworks (ZYME) announced, with Jazz Pharmaceuticals (JAZZ), that the U.S. FDA has granted accelerated approval of Ziihera 50mg/mL for injection ...

Jazz Pharmaceuticals (JAZZ) stock and Zymeworks (ZYME) stock gain as FDA clears their cancer therapy Ziihera. Read more here.

Zymeworks (ZYME) has released an update. Don't Miss our Black Friday Offers: Zymeworks has achieved a significant milestone with the FDA’s accelerated approval of Ziihera, a dual HER2-targeted ...

Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with ...

The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated ...

This event, led by Paul Moore, PhD, Zymeworks’ Chief Scientific Officer, will feature: Updates on our portfolio of solid tumor targeting antibody-drug conjugates and T-cell Engager (TCE) molecules, ...